FY2025 · ended Dec 31, 2025 · Revenue $1.24B, +4.3% YoY · Filed Feb 26, 2026
Indivior Pharmaceuticals, Inc. (SUPN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 billion and net income of $210.0 million. Free cash flow was -$93.0 million. As of Sep 30, 2026 it held $332.0 million in cash and investments and $501.0 million in total debt.
Revenue (TTM)
$1.37B
Net income (TTM)
$450.00M
Operating cash flow (TTM)
$96.00M
Free cash flow (TTM)
$31.00M
EPS (TTM)
$3.56
Dividend per share
None
Shares outstanding
125.07M
+0.3% vs prior year
Net cash
$-169.00M
as of Sep 30, 2026
Operating margin
40.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1625297
- Former names
- Indivior Pharmaceuticals, Inc. (until Nov 2, 2026); INDIVIOR PLC (until Jan 8, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B |
| Operating income | $262.0M | $38.0M | — |
| Net income | $210.0M | $7.0M | — |
| Diluted EPS | $1.64 | $0.05 | — |
| Operating cash flow | -$27.0M | $36.0M | -$315.0M |
| Free cash flow | -$93.0M | $7.0M | -$323.0M |
| Total assets | $1.2B | $1.3B | $1.8B |
| Total liabilities | $1.3B | $1.7B | $1.9B |
| Stockholders' equity | -$98.0M | -$337.0M | — |
| Cash and investments | $223.0M | $347.0M | $316.0M |
| Total debt | $351.0M | $375.0M | $357.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
All 572 Indivior Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.